Compare Stocks

Date Range: 

 Viela BioKaruna TherapeuticsOPKO HealthTaro Pharmaceutical IndustriesPacira BioSciences
SymbolNASDAQ:VIENASDAQ:KRTXNASDAQ:OPKNYSE:TARONASDAQ:PCRX
Price Information
Current Price$53.01$107.55$4.08$75.18$61.95
52 Week RangeHoldBuyBuyBuyBuy
MarketRank™
Overall Score0.81.81.90.91.9
Analysis Score1.14.53.51.52.3
Community Score1.23.02.52.22.9
Dividend Score0.00.00.00.00.0
Ownership Score0.81.71.70.00.0
Earnings & Valuation Score0.60.01.90.64.4
Analyst Ratings
Consensus RecommendationHoldBuyBuyBuyBuy
Consensus Price Target$57.00$147.70$9.00$81.00$76.75
% Upside from Price Target7.53% upside37.33% upside120.59% upside7.74% upside23.89% upside
Trade Information
Market Cap$2.91 billion$3.17 billion$2.73 billion$2.85 billion$2.72 billion
Beta0.432.071.980.921.27
Average Volume1,065,058194,7606,788,47728,988481,222
Sales & Book Value
Annual Revenue$50 millionN/A$901.90 million$644.77 million$421.03 million
Price / Sales58.26N/A3.034.466.48
CashflowN/AN/AN/A$6.78 per share$1.46 per share
Price / CashN/AN/AN/A11.0942.56
Book Value$7.14 per share$16.65 per share$2.43 per share$55.15 per share$8.51 per share
Price / Book7.42N/A1.681.367.28
Profitability
Net Income$-86,430,000.00$-43,960,000.00$-314,920,000.00$244.24 million$-11,020,000.00
EPS($7.02)($3.68)($0.41)$6.35$0.86
Trailing P/E RatioN/AN/AN/AN/A21.81
Forward P/E RatioN/AN/A68.0017.9421.51
P/E GrowthN/AN/A5.84N/A0.82
Net MarginsN/AN/A-9.79%-45.94%29.95%
Return on Equity (ROE)-33.97%-13.91%-2.61%10.36%10.71%
Return on Assets (ROA)-31.49%-13.72%-1.80%8.38%4.88%
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity RatioN/AN/A0.13%N/A0.78%
Current Ratio19.51%70.57%1.27%2.53%7.63%
Quick Ratio19.49%70.56%0.94%2.25%6.84%
Ownership Information
Institutional Ownership Percentage46.98%74.83%28.51%11.23%N/A
Insider Ownership Percentage31.50%18.10%40.90%13.80%5.80%
Miscellaneous
Employees166635,2691,464624
Shares Outstanding54.95 million29.46 million670.15 million38.26 million44.01 million
Next Earnings Date5/12/2021 (Estimated)5/6/2021 (Estimated)7/29/2021 (Estimated)5/18/2021 (Estimated)8/5/2021 (Estimated)
OptionableNot OptionableNot OptionableOptionableOptionableOptionable
SourceHeadline
Pacira BioSciences (NASDAQ:PCRX) Issues Quarterly Earnings Results, Misses Expectations By $0.11 EPSPacira BioSciences (NASDAQ:PCRX) Issues Quarterly Earnings Results, Misses Expectations By $0.11 EPS
americanbankingnews.com - May 5 at 5:58 PM
Relative Strength Alert For Pacira BioSciencesRelative Strength Alert For Pacira BioSciences
nasdaq.com - May 5 at 12:29 PM
Paciras (PCRX) Q1 Earnings Lag Estimates, Revenues BeatPacira's (PCRX) Q1 Earnings Lag Estimates, Revenues Beat
finance.yahoo.com - May 5 at 12:29 PM
Northland Securities Trims Pacira BioSciences (NASDAQ:PCRX) Target Price to $66.00Northland Securities Trims Pacira BioSciences (NASDAQ:PCRX) Target Price to $66.00
americanbankingnews.com - May 5 at 11:35 AM
Pacira BioSciences (NASDAQ:PCRX) Given New $66.00 Price Target at Northland SecuritiesPacira BioSciences (NASDAQ:PCRX) Given New $66.00 Price Target at Northland Securities
americanbankingnews.com - May 5 at 11:35 AM
Pacira (PCRX) Q1 Earnings Lag EstimatesPacira (PCRX) Q1 Earnings Lag Estimates
finance.yahoo.com - May 4 at 1:31 PM
Pacira: Q1 Earnings SnapshotPacira: Q1 Earnings Snapshot
sfgate.com - May 4 at 8:31 AM
Pacira BioSciences Reports First Quarter 2021 Financial Results and Business UpdatePacira BioSciences Reports First Quarter 2021 Financial Results and Business Update
finance.yahoo.com - May 4 at 8:31 AM
Pacira BioSciences, Inc. (NASDAQ:PCRX) Received A 21.34% Gain In 6 Months – Here’s What To ExpectPacira BioSciences, Inc. (NASDAQ:PCRX) Received A 21.34% Gain In 6 Months – Here’s What To Expect
marketingsentinel.com - May 1 at 11:50 AM
Pacira BioSciences, Inc.s (NASDAQ:PCRX) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock?Pacira BioSciences, Inc.'s (NASDAQ:PCRX) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock?
nasdaq.com - April 30 at 10:57 PM
Pre-earnings Momentum Trade With a Technical Trigger in Pacira BioSciences IncPre-earnings Momentum Trade With a Technical Trigger in Pacira BioSciences Inc
cmlviz.com - April 24 at 6:06 PM
Pacira BioSciences (NASDAQ:PCRX) Shares Gap Up to $62.65Pacira BioSciences (NASDAQ:PCRX) Shares Gap Up to $62.65
americanbankingnews.com - April 22 at 11:36 AM
Pacira invests in biopharmaceutical companyPacira invests in biopharmaceutical company
beckersspine.com - April 21 at 8:16 PM
Pacira to Report First Quarter 2021 Financial Results on Tuesday May 4, 2021Pacira to Report First Quarter 2021 Financial Results on Tuesday May 4, 2021
finance.yahoo.com - April 21 at 10:15 AM
Wedbush Stick to Their Buy Rating for Pacira PharmaceuticalsWedbush Stick to Their Buy Rating for Pacira Pharmaceuticals
investing.com - April 20 at 10:34 PM
Pacira BioSciences Announces Investment in Spine BioPharmaPacira BioSciences Announces Investment in Spine BioPharma
finance.yahoo.com - April 20 at 12:33 PM
Spine BioPharma Announces Investment by Pacira BiosciencesSpine BioPharma Announces Investment by Pacira Biosciences
finance.yahoo.com - April 20 at 12:33 PM
Drug Company Sues Medical JournalDrug Company Sues Medical Journal
khn.org - April 16 at 1:27 PM
Pacira BioSciences Alleges American Society of Anesthesiologists ‘Disparaged’ Drug in Medical JournalPacira BioSciences Alleges American Society of Anesthesiologists ‘Disparaged’ Drug in Medical Journal
lawstreetmedia.com - April 16 at 1:27 PM
Insider Selling: Pacira BioSciences, Inc. (NASDAQ:PCRX) Insider Sells 21,823 Shares of StockInsider Selling: Pacira BioSciences, Inc. (NASDAQ:PCRX) Insider Sells 21,823 Shares of Stock
americanbankingnews.com - April 15 at 10:32 PM
A drug maker sues a medical journal, its editor, and several authors for libelA drug maker sues a medical journal, its editor, and several authors for libel
statnews.com - April 15 at 7:22 PM
Pacira BioSciences, Inc. (NASDAQ:PCRX) Receives Average Rating of "Buy" from BrokeragesPacira BioSciences, Inc. (NASDAQ:PCRX) Receives Average Rating of "Buy" from Brokerages
americanbankingnews.com - April 15 at 2:34 PM
Pacira BioSciences (NASDAQ:PCRX) Receives New Coverage from Analysts at Berenberg BankPacira BioSciences (NASDAQ:PCRX) Receives New Coverage from Analysts at Berenberg Bank
americanbankingnews.com - April 15 at 9:50 AM
Pacira BioSciences Seeks Court Injunction to Protect Clinical Integrity of EXPAREL in the Face ...Pacira BioSciences Seeks Court Injunction to Protect Clinical Integrity of EXPAREL in the Face ...
apnews.com - April 14 at 7:51 PM
Pacira BioSciences Seeks Court Injunction to Protect Clinical Integrity of EXPAREL in the Face of Scientifically Flawed and Misleading Information Published in AnesthesiologyPacira BioSciences Seeks Court Injunction to Protect Clinical Integrity of EXPAREL in the Face of Scientifically Flawed and Misleading Information Published in Anesthesiology
finance.yahoo.com - April 14 at 7:51 PM
Pacira BioSciences (NASDAQ:PCRX) Coverage Initiated by Analysts at Berenberg BankPacira BioSciences (NASDAQ:PCRX) Coverage Initiated by Analysts at Berenberg Bank
marketbeat.com - April 9 at 7:40 AM
DateCompanyBrokerageAction
2/8/2021Viela BioGuggenheimDowngrade
2/8/2021Viela BioWedbushDowngrade
2/2/2021Viela BioHC WainwrightDowngrade
8/13/2020Viela BioStifel NicolausReiterated Rating
7/15/2020Viela BioThe Goldman Sachs GroupUpgrade
6/3/2020Viela BioCowenReiterated Rating
5/14/2020Viela BioMorgan StanleyBoost Price Target
3/29/2021Karuna TherapeuticsBank of AmericaInitiated Coverage
3/8/2021Karuna TherapeuticsOppenheimerBoost Price Target
3/4/2021Karuna TherapeuticsJMP SecuritiesBoost Price Target
3/4/2021Karuna TherapeuticsMizuhoBoost Price Target
2/26/2021Karuna TherapeuticsMaxim GroupReiterated Rating
2/9/2021Karuna TherapeuticsRoyal Bank of CanadaInitiated Coverage
1/5/2021Karuna TherapeuticsWilliam BlairReiterated Rating
2/19/2021OPKO HealthBarrington ResearchBoost Price Target
7/31/2020OPKO HealthPiper SandlerBoost Price Target
11/25/2019OPKO HealthPiper Jaffray CompaniesInitiated Coverage
8/7/2018OPKO HealthCantor FitzgeraldReiterated Rating
5/5/2021Pacira BioSciencesNorthland SecuritiesLower Price Target
4/15/2021Pacira BioSciencesBerenberg BankInitiated Coverage
2/26/2021Pacira BioSciencesBarclaysBoost Price Target
1/21/2021Pacira BioSciencesSVB LeerinkDowngrade
1/8/2021Pacira BioSciencesNeedham & Company LLCBoost Price Target
9/30/2020Pacira BioSciencesJefferies Financial GroupBoost Price Target
8/14/2020Pacira BioSciencesTruistBoost Price Target
(Data available from 5/5/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
Comparison Ideas:

As Featured By:

MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.